The re-dose of ISP-001 has been well-tolerated, to date, and Immusoft continues to observe positive results SAN FRANCISCO, Oct. 7, 2025

Prospectively designed for scalability and re-dosability, Immusoft's engineered B cells represent the next generation of advanced therapeutics SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/

Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028

Preclinical studies in nonhuman primates naturally infected with T. cruzi have shown AN2-502998's curative potential in chronic Chagas disease No

Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC) Phase 1 first

MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 3, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing

AN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint Goal to Accelerate Unblinding Phase 3 Data in Q2 2025

MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 20, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing

MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 29, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing